Publications by authors named "Y Kunishima"
Introduction: We aimed to evaluate the efficacy and safety of enfortumab vedotin therapy for a cohort of older Japanese patients with metastatic urothelial carcinoma compared to younger patients.
Materials And Methods: We retrospectively evaluated patients with metastatic urothelial carcinoma treated with enfortumab vedotin and recruited between April 2019 and February 2023. Older patients were defined as being ≥75 years old.
Purpose: To explore pre-treatment risk factors for overall survival (OS) in advanced urothelial carcinoma (UC) patients treated with first-line (1L) chemotherapy in sequential therapy (ST) era. Additionally, to evaluate the proportion of patients who were not able to undergo subsequent immune checkpoint inhibitor (ICI) therapy according to the subgroups stratified by the risk factors.
Methods: A multicenter retrospective study was conducted.
Enterovirus D68 (EV-D68), a pathogen that causes respiratory symptoms, mainly in children, has been implicated in acute flaccid myelitis, which is a poliomyelitis-like paralysis. Currently, there are no licensed vaccines or treatments for EV-D68 infections. Here, we investigated the optimal viral inactivation reagents, vaccine adjuvants, and route of vaccination in mice to optimize an inactivated whole-virion (WV) vaccine against EV-D68.
View Article and Find Full Text PDFArticle Synopsis
- A study compared the effectiveness of pembrolizumab and avelumab, two immune checkpoint inhibitors, in treating patients with advanced urothelial carcinoma who had previously undergone chemotherapy.
- Researchers examined patient records from January 2018 to February 2023, focusing on progression-free survival, overall survival, and immune-related adverse events.
- Results indicated no significant differences in survival outcomes between the two treatments, but pembrolizumab showed a potential risk for higher endocrine-related adverse effects compared to avelumab.
Article Synopsis
- The study aimed to assess how effective local radiation therapy (LRT) is in preventing local symptoms associated with muscle-invasive bladder cancer (MIBC) by reviewing 133 patient records over five years.
- Out of 114 patients analyzed, 26.3% experienced local symptoms such as hematuria and bladder pain, with certain risk factors like previous non-MIBC and lower radiation doses identified.
- The findings suggest that increasing the radiation dose to 50 Gray or more could help reduce these local symptoms and improve care strategies for MIBC patients expected to have good survival outcomes.